Summary:
- Oliver Wyman, part of Marsh McLennan (MMC, Financial), plans to acquire Validate Health to strengthen actuarial services.
- Wall Street analysts suggest a potential 7.99% upside for MMC stock, with an average price target of $234.72.
- The GF Value estimate indicates a 14.04% upside, marking MMC as potentially undervalued.
Strategic Acquisition in Healthcare Analytics
Marsh McLennan's (MMC) consulting division, Oliver Wyman, has announced its intent to acquire Validate Health, a renowned provider of healthcare analytics. This acquisition aims to bolster Oliver Wyman's actuarial services, introducing advanced solutions designed to fuel market growth, enhance operational efficiency, and improve patient outcomes. Specific financial details of the transaction remain undisclosed.
Wall Street Analysts' Insight
According to insights from 17 financial analysts, Marsh & McLennan Companies Inc (MMC, Financial) has a projected one-year price target of $234.72. Projections range from a high estimate of $263.00 to a low estimate of $189.21. Compared to its current trading price of $217.35, this average target suggests a promising upside potential of 7.99%. For a deeper dive into these projections, visit our Marsh & McLennan Companies Inc (MMC) Forecast page.
Brokerage Recommendations
The consensus recommendation across 21 brokerage firms places MMC's average recommendation at 2.9, which implies a "Hold" status. This recommendation scale ranges from 1, indicating a Strong Buy, to 5, marking a Sell.
GuruFocus Value Estimation
According to GuruFocus metrics, the estimated GF Value for Marsh & McLennan Companies Inc (MMC, Financial) stands at $247.85 for the upcoming year. This estimate points to a potential upside of 14.04% from its current stock price of $217.345. The GF Value represents GuruFocus' calculated fair value based on historical trading multiples, past business growth, and future performance projections. Explore more detailed valuations on the Marsh & McLennan Companies Inc (MMC) Summary page.